Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jan 13;1(1):CD011888.
doi: 10.1002/14651858.CD011888.pub2.

Aspirin for acute treatment of episodic tension-type headache in adults

Sheena Derry  1 , Philip J Wiffen  1 , R Andrew Moore  1
Affiliations
Meta-Analysis

Aspirin for acute treatment of episodic tension-type headache in adults

Sheena Derry et al. Cochrane Database Syst Rev. .

Abstract

Background: Tension-type headache (TTH) affects about 1 person in 5 worldwide. It is divided into infrequent episodic TTH (fewer than one headache per month), frequent episodic TTH (two to 14 headache days per month), and chronic TTH (15 headache days per month or more). Aspirin is one of a number of analgesics suggested for acute treatment of episodic TTH.

Objectives: To assess the efficacy and safety of aspirin for acute treatment of episodic tension-type headache (TTH) in adults compared with placebo or any active comparator.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and the Oxford Pain Relief Database from inception to September 2016, and also reference lists of relevant published studies and reviews. We sought unpublished studies by asking personal contacts and searching online clinical trial registers and manufacturers' websites.

Selection criteria: We included randomised, double-blind, placebo-controlled studies (parallel-group or cross-over) using oral aspirin for symptomatic relief of an acute episode of TTH. Studies had to be prospective, with participants aged 18 years or over, and include at least 10 participants per treatment arm.

Data collection and analysis: Two review authors independently assessed studies for inclusion and extracted data. For various outcomes (predominantly those recommended by the International Headache Society (IHS)), we calculated the risk ratio (RR) and number needed to treat for one additional beneficial outcome (NNT), one additional harmful outcome (NNH), or to prevent one event (NNTp) for oral aspirin compared to placebo or an active intervention.We assessed the evidence using GRADE and created a 'Summary of findings' table.

Main results: We included five studies enrolling adults with frequent episodic TTH; 1812 participants took medication, of which 767 were included in comparisons of aspirin 1000 mg with placebo, and 405 in comparisons of aspirin 500 mg or 650 mg with placebo. Not all of these participants provided data for outcomes of interest in this review. Four studies specified using IHS diagnostic criteria; one predated commonly recognised criteria, but described comparable characteristics and excluded migraine. All participants treated headaches of at least moderate pain intensity.None of the included studies were at low risk of bias across all domains considered, although for most studies and domains this was likely to be due to inadequate reporting rather than poor methods. We judged one study to be at high risk of bias due to small size.There were no data for aspirin at any dose for the IHS preferred outcome of being pain free at two hours, or for being pain free at any other time, and only one study provided data equivalent to having no or mild pain at two hours (very low quality evidence). Use of rescue medication was lower with aspirin 1000 mg than with placebo (2 studies, 397 participants); 14% of participants used rescue medication with aspirin 1000 mg compared with 31% with placebo (NNTp 6.0, 95% confidence interval (CI) 4.1 to 12) (low quality evidence). Two studies (397 participants) reported a Patient Global Evaluation at the end of the study; we combined the top two categories for both studies to determine the number of participants who were 'satisfied' with treatment. Aspirin 1000 mg produced more satisfied participants (55%) than did placebo (37%) (NNT 5.7, 95% CI 3.7 to 12) (very low quality evidence).Adverse events were not different between aspirin 1000 mg and placebo (RR 1.1, 95% CI 0.8 to 1.5), or aspirin 500 mg or 650 mg and placebo (RR 1.3, 95% CI 0.8 to 2.0) (low quality evidence). Studies reported no serious adverse events.The quality of the evidence using GRADE comparing aspirin doses between 500 mg and 1000 mg with placebo was low or very low. Evidence was downgraded because of the small number of studies and events, and because the most important measures of efficacy were not reported.There were insufficient data to compare aspirin with any active comparator (paracetamol alone, paracetamol plus codeine, peppermint oil, or metamizole) at any of the doses tested.

Authors' conclusions: A single dose of aspirin between 500 mg and 1000 mg provided some benefit in terms of less frequent use of rescue medication and more participants satisfied with treatment compared with placebo in adults with frequent episodic TTH who have an acute headache of moderate or severe intensity. There was no difference between a single dose of aspirin and placebo for the number of people experiencing adverse events. The amount and quality of the evidence was very limited and should be interpreted with caution.

PubMed Disclaimer

Conflict of interest statement

SD: none known.

PW: none known.

RAM has received grant support from Grünenthal relating to individual patient level analyses of trial data regarding tapentadol in osteoarthritis and back pain (2015). He has received honoraria for attending boards with Menarini concerning methods of analgesic trial design (2014), with Novartis (2014) about the design of network meta‐analyses, and RB on understanding pharmacokinetics of drug uptake (2015). He has received honoraria from Omega Pharma (2016) and Futura Pharma (2016) for providing advice on trial and data analysis methods.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Aspirin 1000 mg versus placebo, Outcome 1 Participants using rescue medication.
1.2
1.2. Analysis
Comparison 1 Aspirin 1000 mg versus placebo, Outcome 2 Participant global evaluation: 'satisfied'.
1.3
1.3. Analysis
Comparison 1 Aspirin 1000 mg versus placebo, Outcome 3 Participants with any adverse event.
2.1
2.1. Analysis
Comparison 2 Aspirin 500 mg or 650 mg versus placebo, Outcome 1 Participants with any adverse event.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011888

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Gatoulis 2012 {published data only}
    1. Gatoulis SG, Voelker M, Fisher M. Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension‐type headache and postoperative dental pain. Clinical Therapeutics 2012;34(1):138‐48. [DOI: 10.1016/j.clinthera.2011.11.018] - DOI - PubMed
Göbel 2001 {published data only}
    1. Göbel H, Heinze A, Dworschak M, Heinze‐Kuhn K, Stolze H. Analgesic efficacy and tolerability of locally applied Oleum menthae piperitae preparation LI 170 in patients with migraine or tension‐type headache [German] [Wirksamkeit und verträglichkeit von oleum‐menthaepiperitae‐lösung LI 170 bei kopfschmerz vom spannungstyp und migräne]. Zeitschrift fur Allgemeinmedizin 2001;77(6):287‐95.
Martínez‐Martín 2001 {published data only}
    1. Martínez‐Martín P, Raffaelli E Jr, Titus F, Despuig J, Fragoso YD, Díez‐Tejedor E, et al. Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension‐type headache: a randomised, double‐blind, placebo‐ and active‐controlled, multicentre study. Cephalalgia 2001;21(5):604‐10. [DOI: 10.1046/j.1468-2982.2001.00216.x] - DOI - PubMed
Peters 1983 {published data only}
    1. Peters BH, Fraim CJ, Masel BE. Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. American Journal of Medicine 1983;74(6A):36‐42. [DOI: 10.1016/0002-9343(83)90526-0] - DOI - PubMed
Steiner 2003 {published data only}
    1. Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalalgia 2003;23(1):59‐66. [DOI: 10.1046/j.1468-2982.2003.00470.x] - DOI - PubMed

References to studies excluded from this review

Diamond 1983 {published data only}
    1. Diamond S. Ibuprofen versus aspirin and placebo in the treatment of muscle contraction headache. Headache 1983;23(5):206‐10. [DOI: 10.1111/j.1526-4610.1983.hed2305206.x] - DOI - PubMed
Diener 2005 {published data only}
    1. Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomised, double‐blind, single‐dose, placebo‐controlled parallel group study. Cephalalgia 2005;25(10):776‐87. [DOI: 10.1111/j.1468-2982.2005.00948.x] - DOI - PubMed
Glassman 1982 {published data only}
    1. Glassman JM, Soyka JP, Pollack M. Treatment of muscle contraction headache: Micrainin vs. aspirin. Headache 1982;22(3):101‐9. [DOI: 10.1111/j.1526-4610.1982.hed2203101.x] - DOI - PubMed
Langemark 1987 {published data only}
    1. Langemark M. Effervescent aspirin in the treatment of tension headache. A double blind, placebo controlled cross‐over study. Cephalalgia 1985;5 (Suppl 3):152‐3.
    1. Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of tension headache. A double‐blind, placebo controlled study. Headache 1987;27(2):90‐5. [10.1111/j.1526‐4610.1987.hed2702090.x] - PubMed
NCT01552798 {unpublished data only}
    1. Bayer (Responsible Party). A double‐blind, randomized, parallel, placebo‐controlled trial assessing the analgesic efficacy of a single dose of fast release aspirin 1000 mg and acetaminophen 1000 mg in tension type headache pain. clinicaltrials.gov/ct2/show/NCT01552798 (accessed 6 September 2016). [CTG: NCT01552798]
Nebe 1995 {published data only}
    1. Nebe J, Heier M, Diener HC. Low‐dose ibuprofen in self‐medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995;15(6):531‐5. [PUBMED: 8706118] - PubMed
Ryan 1977 {published data only}
    1. Ryan RE. Motrin ‐ a new agent for the symptomatic treatment of muscle contraction headache. Headache 1977;16(6):280‐3. [PUBMED: 830617] - PubMed
von Graffenried 1980 {published data only}
    1. Wood A, Graffenried B. Fluproquazone: analgesic activity in outpatients with non‐migrainous headache. Arzneimittelforschung 1981;31(5a):914‐7. [PUBMED: 7023493] - PubMed
    1. Graffenried B, Hill RC, Nüesch E. Headache as a model for assessing mild analgesic drugs. Journal of Clinical Pharmacology 1980;20(2‐3):131‐44. [DOI: 10.1002/j.1552-4604.1980.tb02535.x] - DOI - PubMed
    1. Graffenried B, Nüesch E. Non‐migrainous headache for the evaluation of oral analgesics. British Journal of Clinical Pharmacology 1980;10 (Suppl 2):225S‐31S. [DOI: 10.1111/j.1365-2125.1980.tb01804.x] - DOI - PMC - PubMed

References to studies awaiting assessment

NCT01464983 {unpublished data only}
    1. Bayer (Responsible Party). A multicentre randomised parallel‐groups double‐blind double‐dummy single‐dose study to compare acetylsalicylic acid 500 mg and 1,000 mg with ibuprofen 200 mg and 400 mg and placebo for tolerability and efficacy in the treatment of episodic tension‐type headache. clinicaltrials.gov/ct2/show/NCT01464983 (accessed 5 September 2016). [Bayer: 11220; CTG: NCT01464983]

Additional references

BASH 2010
    1. MacGregor EA, Steiner TJ, Davies PTG, for the British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension‐type, cluster, and medication overuse headache. 3rd edition (1st revision). www.bash.org.uk/wp‐content/uploads/2012/07/10102‐BASH‐Guidelines‐update‐... (accessed 6 September 2016).
Bendtsen 2010
    1. Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension‐type headache ‐ report of an EFNS taskforce. European Journal of Neurology 2010;17(11):1318‐25. [DOI: 10.1111/j.1468-1331.2010.03070.x] - DOI - PubMed
Bendtsen 2016
    1. Bendtsen L, Ashina S, Moore A, Steiner TJ. Muscles and their role in episodic tension‐type headache: implications for treatment. European Journal of Pain 2016;20(2):166‐75. [DOI: 10.1002/ejp.748] - DOI - PubMed
BNF 2016
    1. Aspirin. www.medicinescomplete.com/mc/bnf/current/PHP2596‐aspirin.htm. BMJ Group and Pharmaceutical Press, (accessed 30 November 2016). [DOI: 10.18578/BNF.456850132] - DOI
Brainin 2004
    1. Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, et al. for the Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces‐revised recommendations 2004. European Journal of Neurology 2004;11(9):577‐81. [DOI: 10.1111/j.1468-1331.2004.00867.x] - DOI - PubMed
Cook 1995
    1. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452‐4. [DOI: 10.1136/bmj.310.6977.452] - DOI - PMC - PubMed
Cristofolini 2008
    1. Cristofolini A, Dalla Serra P, Scherillo G, Orrico D, Micciolo R. The prevalence of headache in a population of health care workers and the effects on productivity costs. La Medicina del Lavoro 2008;99(1):8‐15. - PubMed
Dechartres 2013
    1. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304] - DOI - PMC - PubMed
Derry 2015
    1. Derry S, Wiffen PJ, Moore RA, Bendtsen L. Ibuprofen for acute treatment of episodic tension‐type headache in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD011474.pub2] - DOI - PMC - PubMed
Drugs.com
    1. Aspirin dosage. www.drugs.com/dosage/aspirin.html (accessed 19 September 2016).
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
EPOC 2015
    1. Effective Practice, Organisation of Care (EPOC). 23. Worksheets for preparing a summary of findings using GRADE. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 30 November 2016).
Fernández‐de‐las‐Peñas 2010
    1. Fernández‐de‐las‐Peñas C, Madeleine P, Caminero AB, Cuadrado ML, Arendt‐Nielsen L, Pareja JA. Generalized neck‐shoulder hyperalgesia in chronic tension‐type headache and unilateral migraine assessed by pressure pain sensitivity topographical maps of the trapezius muscle. Cephalalgia 2010;30(1):77‐86. [DOI: 10.1111/j.1468-2982.2009.01901.x] - DOI - PubMed
Forward 1998
    1. Forward SP, McGrath PJ, MacKinnon D, Brown TL, Swann J, Currie EL. Medication patterns of recurrent headache sufferers: a community study. Cephalalgia 1998;18(3):146‐51. [DOI: 10.1046/j.1468-2982.1998.1803146.x] - DOI - PubMed
Fumal 2008
    1. Fumal A, Schoenen J. Tension‐type headache: current research and clinical management. Lancet Neurology 2008;7(1):70‐83. [DOI: 10.1016/S1474-4422(07)70325-3] - DOI - PubMed
Glasgow 2006
    1. Glasgow JF. Reye's syndrome: the case for a causal link with aspirin. Drug Safety 2006;29(12):1111‐21. [PUBMED: 17147458] - PubMed
Green 2009
    1. Green MW. Primary and secondary headaches. In: Rowland LP, Pedley TA editor(s). Merritt's Neurology. 12th Edition. Philadelphia: Lippincott Williams and Wilkins, 2009:951‐60. [ISBN: 9780781791861]
Guyatt 2013a
    1. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] - DOI - PubMed
Guyatt 2013b
    1. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] - DOI - PubMed
Haag 2011
    1. Haag G, Diener HC, May A, Meyer C, Morck H, Straube A, et al. Self‐medication of migraine and tension‐type headache: summary of the evidence‐based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG). Journal of Headache and Pain 2011;12(2):201‐17. [DOI: 10.1007/s10194-010-0266-4] - DOI - PMC - PubMed
Harpole 2005
    1. Harpole LH, Samsa GP, Matchar DB, Silberstein SD, Blumenfeld A, Jurgelski AE. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache 2005;45(8):1048‐55. [DOI: 10.1111/j.1526-4610.2005.05186.x] - DOI - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
IHS 2004
    1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:1‐160. [DOI: 10.1111/j.1468-2982.2003.00824.x] - DOI - PubMed
IHS 2010
    1. Bendtsen L, Bigal ME, Cerbo R, Diener HC, Holroyd K, Lampl C, et al. on behalf of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in tension‐type headache: second edition. Cephalalgia 2010;30(1):1‐16. [DOI: 10.1111/j.1468-2982.2009.01948.x] - DOI - PubMed
IHS 2013
    1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629‐808. [DOI: 10.1177/0333102413485658] - DOI - PubMed
Jadad 1996a
    1. Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 1996;66(2‐3):239‐46. [DOI: 10.1016/0304-3959(96)03033-3] - DOI - PubMed
Jadad 1996b
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [DOI: 10.1016/0197-2456(95)00134-4] - DOI - PubMed
Kernick 2008
    1. Kernick D, Stapley S, Hamilton W. GPs' classification of headache: is primary headache underdiagnosed?. British Journal of General Practice 2008;58(547):102‐4. [DOI: 10.3399/bjgp08X264072] - DOI - PMC - PubMed
Kirthi 2013
    1. Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008041.pub3] - DOI - PMC - PubMed
L'Abbé 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107(2):224‐33. [DOI: 10.1046/j.1468-2982.1998.1808552.x] - DOI - PubMed
Lyngberg 2005
    1. Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Secular changes in health care utilization and work absence for migraine and tension‐type headache: a population based study. European Journal of Epidemiology 2005;20(12):1007‐14. [DOI: 10.1007/s10654-005-3778-5] - DOI - PubMed
Mannix 2001
    1. Mannix LK. Epidemiology and impact of primary headache disorders. Medical Clinics of North America 2001;85(4):887‐95. [DOI: 10.1016/S0025-7125(05)70349-7] - DOI - PubMed
Monteith 2010
    1. Monteith TS, Sprenger T. Tension type headache in adolescence and childhood: where are we now?. Current Pain and Headache Reports 2010;14(6):424‐30. [DOI: 10.1007/s11916-010-0149-z] - DOI - PMC - PubMed
Moore 1998
    1. Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5]
Moore 2011
    1. Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD008659.pub2] - DOI - PMC - PubMed
Moore 2013
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148] - DOI - PubMed
Moore 2014
    1. Moore RA, Derry S, Wiffen PJ, Straube S, Bendtsen L. Evidence for efficacy of acute treatment of episodic tension‐type headache: methodological critique of randomised trials for oral treatments. Pain 2014;155(11):2220‐8. [DOI: 10.1016/j.pain.2014.08.009] - DOI - PubMed
Morris 1995
    1. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with Confidence ‐ Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50‐63. [ISBN: 0‐7279‐0222‐0] - PMC - PubMed
Nüesch 2010
    1. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515] - DOI - PMC - PubMed
Oshinaike 2014
    1. Oshinaike O, Ojo O, Okubadejo N, Ojelabi O, Dada A. Primary headache disorders at a tertiary health facility in Lagos, Nigeria: prevalence and consultation patterns. Biomedical Research International 2014;2014:782915. [DOI: 10.1155/2014/782915] - DOI - PMC - PubMed
PaPaS 2012
    1. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 6 September 2016).
Pop 2002
    1. Pop PH, Gierveld CM, Karis HA, Tiedink HG. Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. European Journal of Neurology 2002;9(2):171‐4. - PubMed
Rasmussen 2001
    1. Rasmussen BK. Epidemiology of headache. Cephalalgia 2001;21(7):774‐7. [PUBMED: 11595011] - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sahler 2012
    1. Sahler K. Epidemiology and cultural differences in tension‐type headache. Current Pain and Headache Research 2012;16(6):525‐32. [DOI: 10.1007/s11916-012-0296-5] - DOI - PubMed
Steiner 2003
    1. Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension‐type headache: placebo‐controlled dose‐ranging comparison with paracetamol. Cephalalgia 2003;23(1):59‐66. [DOI: 10.1046/j.1468-2982.2003.00470.x] - DOI - PubMed
Steiner 2004
    1. Steiner TJ. Lifting the burden: the global campaign against headache. Lancet Neurology 2004;3(4):204‐5. [DOI: 10.1016/S1474-4422(04)00703-3] - DOI - PubMed
Steiner 2011
    1. Steiner TJ, Stovner LJ, Dua T, Birbeck GL, Jensen R, Katsarava Z, et al. Time to act on headache disorders. Journal of Headache and Pain 2011;12(5):501‐3. [DOI: 10.1007/s10194-011-0368-7] - DOI - PMC - PubMed
Stephens 2016
    1. Stephens G, Derry S, Moore RA. Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults. Cochrane Database of Systematic Reviews 2016, Issue 6. [DOI: 10.1002/14651858.CD011889.pub2] - DOI - PMC - PubMed
Stovner 2007
    1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher AI, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27(3):193‐210. [DOI: 10.1111/j.1468-2982.2007.01288.x] - DOI - PubMed
Tramèr 1997
    1. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate results on meta‐analysis: a case study. BMJ 1997;315(7109):635‐9. [DOI: 10.1136/bmj.315.7109.635] - DOI - PMC - PubMed
Vane 1971
    1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin‐like drugs. Nature: New Biology 1971;231(25):232‐5. [PUBMED: 5284360] - PubMed
Verhagen 2006
    1. Verhagen AP, Damen L, Berger MY, Passchier J, Merlin V, Koes BW. Is any one analgesic superior for episodic tension‐type headache?. Journal of Family Practice 2006;55(12):1064‐72. [PUBMED: 17137543] - PubMed
Veys 2016
    1. Veys L, Derry S, Moore RA. Ketoprofen for episodic tension‐type headache in adults. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD012190.pub2] - DOI - PMC - PubMed
Vos 2012
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163‐96. [DOI: 10.1016/S0140-6736(12)61729-2] - DOI - PMC - PubMed
WHO 2015
    1. World Health Organization. WHO model list of essential medicines, 19th list. www.who.int/medicines/publications/essentialmedicines/en/index.html (accessed 6 September 16).

Publication types

MeSH terms

LinkOut - more resources